Roche Receives the US FDA's Approval for First CDx to Identify Endometrial Cancer Patients Eligible for Immunotherapy
Shots:
- The US FDA has approved Ventana MMR RxDx panel to identify endometrial cancer patients who are eligible for treatment with GSK’s Jemperli (monothx.) that has received the US FDA’s approval on Apr 22- 2021
- The CDx provides clinicians with a standardized testing option that uses a comprehensive panel of DNA mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC)
- Ventana MMR RxDx panel is the first immunohistochemistry predictive test that provides clinicians access to a fully automated- easy-to-use MMR test to identify patients who benefitted from Jemperli (dostarlimab-gxly)
Ref: Globe Newswire | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com